Nivalis Therapeutics Inc. (NASDAQ:NVLS) was downgraded by equities researchers at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research note issued on Tuesday. They presently have a $3.25 price target on the stock, down from their previous price target of $16.00. Stifel Nicolaus’ target price points to a potential downside of 48.00% from the stock’s current price.

Several other research firms have also commented on NVLS. Raymond James Financial Inc. began coverage on shares of Nivalis Therapeutics in a research report on Tuesday, September 13th. They issued an “outperform” rating and a $20.00 price target on the stock. Zacks Investment Research upgraded shares of Nivalis Therapeutics from a “sell” rating to a “buy” rating and set a $8.50 price target on the stock in a research report on Thursday, October 20th. Piper Jaffray Cos. reiterated a “buy” rating and issued a $16.00 price target on shares of Nivalis Therapeutics in a research report on Tuesday, August 30th. HC Wainwright restated a “buy” rating on shares of Nivalis Therapeutics in a research report on Monday, August 8th. Finally, Cowen and Company restated a “buy” rating on shares of Nivalis Therapeutics in a research report on Monday, August 1st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $11.25.

Analyst Recommendations for Nivalis Therapeutics (NASDAQ:NVLS)

Nivalis Therapeutics (NASDAQ:NVLS) opened at 6.25 on Tuesday. Nivalis Therapeutics has a 1-year low of $3.68 and a 1-year high of $9.45. The firm’s market cap is $97.14 million. The firm has a 50 day moving average of $6.46 and a 200 day moving average of $5.84.

Nivalis Therapeutics (NASDAQ:NVLS) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.11. On average, equities research analysts expect that Nivalis Therapeutics will post ($2.10) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Nivalis Therapeutics Inc. (NVLS) Cut to Hold at Stifel Nicolaus” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and republished in violation of United States and international copyright and trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/29/nivalis-therapeutics-inc-nvls-cut-to-hold-at-stifel-nicolaus.html.

In related news, EVP David Malcom Rodman sold 5,820 shares of the firm’s stock in a transaction that occurred on Tuesday, October 4th. The shares were sold at an average price of $7.96, for a total transaction of $46,327.20. Following the sale, the executive vice president now owns 18,056 shares in the company, valued at $143,725.76. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.00% of the company’s stock.

A number of hedge funds have recently made changes to their positions in NVLS. Endurant Capital Management LP raised its stake in shares of Nivalis Therapeutics by 29.8% in the third quarter. Endurant Capital Management LP now owns 85,412 shares of the company’s stock worth $694,000 after buying an additional 19,629 shares during the period. Sphera Funds Management LTD. purchased a new stake in shares of Nivalis Therapeutics during the third quarter worth about $1,664,000. Spark Investment Management LLC purchased a new stake in shares of Nivalis Therapeutics during the third quarter worth about $145,000. Bank of New York Mellon Corp raised its stake in shares of Nivalis Therapeutics by 7.8% in the third quarter. Bank of New York Mellon Corp now owns 16,494 shares of the company’s stock worth $134,000 after buying an additional 1,189 shares during the period. Finally, Paloma Partners Management Co purchased a new stake in shares of Nivalis Therapeutics during the second quarter worth about $105,000. Hedge funds and other institutional investors own 79.26% of the company’s stock.

About Nivalis Therapeutics

Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

5 Day Chart for NASDAQ:NVLS

Receive News & Stock Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related stocks with our FREE daily email newsletter.